

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1614VXK

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,
STN AnaVist, now available
NEWS 4 AUG 11 STN AnaVist workshops to be held in North America
NEWS 5 AUG 30 CA/CAPLUS - Increased access to 19th century research documents
NEWS 6 AUG 30 CASREACT - Enhanced with displayable reaction conditions
NEWS 7 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 8 OCT 03 MATHDI removed from STN
NEWS 9 OCT 04 CA/CAPLUS-Canadian Intellectual Property Office (CIPO) added
to core patent offices
NEWS 10 OCT 06 STN AnaVist workshops to be held in North America
NEWS 11 OCT 13 New CAS Information Use Policies Effective October 17, 2005

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:05:34 ON 15 OCT 2005

=> fil uspatful, caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'USPATFULL' ENTERED AT 17:05:50 ON 15 OCT 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 17:05:50 ON 15 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

=> s bupropion (3a) metabolite
 L1 38 FILE USPATFULL
 L2 50 FILE CAPLUS

TOTAL FOR ALL FILES
 L3 88 BUPROPION (3A) METABOLITE

=> s "propan-1-ol" and l3
 L4 2 FILE USPATFULL
 L5 0 FILE CAPLUS

TOTAL FOR ALL FILES
 L6 2 "PROPAN-1-OL" AND L3

=> d 1-2 ibib

L6 ANSWER 1 OF 2 USPATFULL on STN
 ACCESSION NUMBER: 2002:99440 USPATFULL
 TITLE: **Bupropion metabolites** and methods
 of their synthesis and use
 INVENTOR(S): Fang, Kevin Qun, Wellesley, MA, UNITED STATES
 Senanayake, Chrisantha Hugh, Shrewsbury, MA, UNITED
 STATES
 Grover, Paul, Franklin, MA, UNITED STATES
 PATENT ASSIGNEE(S): SEPRACOR INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002052341	A1	20020502
APPLICATION INFO.:	US 2001-987931	A1	20011116 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-640725, filed on 18 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-510241, filed on 22 Feb 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-122277P	19990301 (60)
	US 1999-148324P	19990811 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000, WASHINGTON, DC, 20006	
NUMBER OF CLAIMS:	126	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	2344	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L6 ANSWER 2 OF 2 USPATFULL on STN
 ACCESSION NUMBER: 2002:5997 USPATFULL
 TITLE: **Bupropion metabolites** and methods
 of use
 INVENTOR(S): Fang, Qun Kevin, Wellesley, MA, United States
 Senanayake, Chrisantha Hugh, Shrewsbury, MA, United
 States
 Grover, Paul, Franklin, MA, United States
 PATENT ASSIGNEE(S): Sepracor, Inc., Marlborough, MA, United States (U.S.
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6337328	B1	20020108

APPLICATION INFO.: US 2000-640725 20000818 (9)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-510241, filed
on 22 Feb 2000

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-148324P	19990811 (60)
	US 1999-122277P	19990301 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Jarvis, William R. A.	
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP	
NUMBER OF CLAIMS:	94	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	2461	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> select
ENTER ANSWER SET OR SMARTSELECT L# OR (L6):16
ENTER ANSWER NUMBER OR RANGE (1-):2
ENTER DISPLAY CODE (TI) OR ?:rn
E1 THROUGH E47 ASSIGNED

=> d sel

E1	2	109889-09-0/RN
E2	2	112727-80-7/RN
E3	2	34911-55-2/RN
E4	2	364-62-5/RN
E5	2	83863-69-8/RN
E6	2	89565-68-4/RN
E7	2	90182-92-6/RN
E8	2	99614-02-5/RN
E9	1	102141-11-7/RN
E10	1	102141-12-8/RN
E11	1	106083-71-0/RN
E12	1	124-68-5/RN
E13	1	153365-82-3/RN
E14	1	18162-48-6/RN
E15	1	192374-14-4/RN
E16	1	192374-15-5/RN
E17	1	287477-53-6/RN
E18	1	291275-45-1/RN
E19	1	291275-46-2/RN
E20	1	292055-71-1/RN
E21	1	292055-72-2/RN
E22	1	31677-93-7/RN
E23	1	32634-66-5/RN
E24	1	34841-35-5/RN
E25	1	34911-51-8/RN
E26	1	357399-43-0/RN
E27	1	357399-44-1/RN
E28	1	357628-59-2/RN
E29	1	357628-60-5/RN
E30	1	357628-62-7/RN
E31	1	357628-63-8/RN
E32	1	357628-64-9/RN
E33	1	357637-16-2/RN
E34	1	357637-18-4/RN
E35	1	386210-39-5/RN
E36	1	386210-40-8/RN
E37	1	386210-41-9/RN
E38	1	50-67-9/RN

E39	1	51-41-2/RN
E40	1	51-61-6/RN
E41	1	80478-42-8/RN
E42	1	80478-43-9/RN
E43	1	82801-49-8/RN
E44	1	87-69-4/RN
E45	1	92264-81-8/RN
E46	1	92264-82-9/RN
E47	1	99102-04-2/RN

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

17.50

17.71

FILE 'REGISTRY' ENTERED AT 17:08:45 ON 15 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 OCT 2005 HIGHEST RN 865347-39-3

DICTIONARY FILE UPDATES: 14 OCT 2005 HIGHEST RN 865347-39-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

 *
 * The CA roles and document type information have been removed from *
 * the IDE default display format and the ED field has been added, *
 * effective March 20, 2005. A new display format, IDERL, is now *
 * available and contains the CA role and document type information. *
 *

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s e26

L7 1 357399-43-0/RN

=> d

L7 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 357399-43-0 REGISTRY


ED Entered STN: 19 Sep 2001

CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-Hydroxy-2-(3-chlorophenyl)-3,5,5-trimethylmorpholine

FS 3D CONCORD
MF C13 H18 Cl N O2
SR CA
LC STN Files: CA, CAPLUS, CHEMCATS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> s el8

L8 1 291275-45-1/RN

=> d

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 291275-45-1 REGISTRY
ED Entered STN: 27 Sep 2000
CN Silane, [[[1Z)-1-(3-chlorophenyl)-1-propenyl]oxy](1,1-dimethylethyl)dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H23 Cl O Si
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s el


L9 1 109889-09-0/RN

=> d

L9 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 109889-09-0 REGISTRY

ED Entered STN: 15 Aug 1987
 CN 1H-Indazole-3-carboxamide, 1-methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 1H-Indazole-3-carboxamide, 1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-, endo-
 CN 9-Azabicyclo[3.3.1]nonane, 1H-indazole-3-carboxamide deriv.
 OTHER NAMES:
 CN BRL 43694
 CN BRL 43964
 CN Granisetron
 CN Kevatril
 FS STEREOSEARCH
 DR 121061-98-1
 MF C18 H24 N4 O
 CI COM
 SR World Health Organization (WHO)
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHM, DDFU, DIOGENES, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, NIOSHTIC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: WHO

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

587 REFERENCES IN FILE CA (1907 TO DATE)
 14 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 590 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e2

L10 1 112727-80-7/RN

=> d

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 112727-80-7 REGISTRY

ED Entered STN: 06 Feb 1988

CN Benzamide, 4-amino-N-(1R,4S,5R)-1-azabicyclo[3.3.1]non-4-yl-5-chloro-2-methoxy-, rel- (9CI) (CA INDEX NAME)


OTHER CA INDEX NAMES:

CN 1-Azabicyclo[3.3.1]nonane, benzamide deriv.

CN Benzamide, 4-amino-N-1-azabicyclo[3.3.1]non-4-yl-5-chloro-2-methoxy-,

endo-(±)-
 OTHER NAMES:
 CN Benzamide, 4-amino-N-1-azabicyclo[3.3.1]non-4-yl-5-chloro-2-methoxy-,
 endo-
 CN Renzapride
 CN [(±)-endo]-4-Amino-5-chloro-2-methoxy-N-(1-azabicyclo[3.3.1]non-4-yl)benzamide
 FS STEREOSEARCH
 DR 125636-29-5, 109828-31-1
 MF C16 H22 Cl N3 O2
 CI COM
 SR CA
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, BIOBUSINESS, BIOSIS, CA, CAPLUS, CASREACT, CIN, IMSDRUGNEWS, IMSRESEARCH, IPA, MRCK*, PROMT, PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: WHO

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

96 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 96 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e3

L11 1 34911-55-2/RN

=> d

L11 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 34911-55-2 REGISTRY

ED Entered STN: 16 Nov 1984

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, (±)-

OTHER NAMES:

CN (±)-Bupropion

CN α-(tert-Butylamino)-m-chloropropiophenone

CN Amfebutamon

CN Amfebutamone


CN Bupropion

CN Bupropion SR

DR 34841-39-9

MF C13 H18 Cl N O

CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
 CHEMCATS, CIN, CSChem, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB,
 IFIPAT, IFIUDb, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE,
 MRCK*, PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SPECINFO,
 SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

800 REFERENCES IN FILE CA (1907 TO DATE)
 16 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 804 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e4

L12 1 364-62-5/RN

=> d

L12 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 364-62-5 REGISTRY

ED Entered STN: 16 Nov 1984

CN Benzamide, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy- (9CI)
 (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN o-Anisamide, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]- (7CI, 8CI)

OTHER NAMES:

CN 2-Methoxy-4-amino-5-chloro-N,N-dimethylaminoethylbenzamide

CN 2-Methoxy-5-chloroprocaïnamide

CN 4-Amino-5-chloro-2-methoxy-N-(β-diethylaminoethyl)benzamide

CN 4-Amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide

CN 4-Amino-5-chloro-N-[2-(diethylamino)ethyl]-o-anisamide

CN 4-Amino-5-chloro-N-[2-(diethylamino)ethyl]-o-anisamide

CN 5-Chloro-2-methoxyprocaïnamide

CN AHR 3070C

CN Clopromate

CN DEL 1267

CN Draclamid

CN Emperal

CN Eucil

CN Gastrese

CN Gastro-tablinen

CN Gastro-Timelets

CN Gastrobid


CN Gastromax

CN Gastrosil

CN Gastrotem

CN Maxeran

CN MCP-ratiopharm
 CN Meclopran
 CN Metamide
 CN Methochlopramide
 CN Metochlopramide
 CN Metoclol
 CN Metoclopramide
 CN Metocobil
 CN Metramid
 CN Moriperan
 CN N-(2-Diethylaminoethyl)-2-methoxy-4-amino-5-chlorobenzamide
 CN N-(Diethylaminoethyl)-2-methoxy-4-amino-5-chlorobenzamide
 CN N-(Diethylaminoethyl)-2-methoxy-4-amino-5-chlorobenzamide
 CN N-[2-(Diethylamino)ethyl]-4-amino-5-chloro-2-methoxybenzamide
 CN Parmid
 CN Plasil
 CN Plasil (pharmaceutical)
 CN Primperan
 CN Regla
 CN Reliveran
 FS 3D CONCORD
 MF C14 H22 Cl N3 O2
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS,
 CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHM, DDFU, DIOGENES, DRUGU,
 EMBASE, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS,
 IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, PROMT,
 PROUSDDR, PS, RTECS*, SCISEARCH, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT,
 USAN, USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2327 REFERENCES IN FILE CA (1907 TO DATE)
 21 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 2331 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 15 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s e5

L13 1 83863-69-8/RN


=> d

L13 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 83863-69-8 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[(3R,4S)-3-methoxy-4-piperidinyl]-
 , rel- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Benzamide, 4-amino-5-chloro-2-methoxy-N-(3-methoxy-4-piperidinyl)-, cis-

OTHER NAMES:

CN (±)-Norcisapride
 CN Norcisapride
 FS STEREOSEARCH
 DR 86718-38-9
 MF C14 H20 Cl N3 O3
 SR European Union (EU)
 LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN,
 IMSRESEARCH, PHAR, TOXCENTER, USPAT2, USPATFULL
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

35 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 35 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e6

L14 1 89565-68-4/RN

=> d

L14 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 89565-68-4 REGISTRY

ED Entered STN: 16 Nov 1984

CN 1H-Indole-3-carboxylic acid, (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl
 ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1H-Indole-3-carboxylic acid, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester,
 endo-

OTHER NAMES:

CN ICS 205-930

CN ICS 205930

CN Navoban

CN Tropisetron

FS STEREOSEARCH

DR 121061-97-0


MF C17 H20 N2 O2

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CBNB, CHEMCATS,
 CIN, CSCHEM, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH,
 IPA, MEDLINE, MRCK*, NIOSHTIC, PATDPASPC, PHAR, PROMT, PROUSDDR, PS,
 RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)

Other Sources: WHO

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


540 REFERENCES IN FILE CA (1907 TO DATE)
11 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
541 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e7

L15 1 90182-92-6/RN

=> d

L15 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 90182-92-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzamide, 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy- (9CI)
(CA INDEX NAME)
OTHER NAMES:
CN (±)-Zacopride
CN (RS)-Zacopride
CN Racemic zacopride
CN Zacopride
FS 3D CONCORD
DR 131104-11-5
MF C15 H20 Cl N3 O2
CI COM
LC STN Files: ADISINSIGHT, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA,
CANCERLIT, CAPLUS, CASREACT, CEN, DDFU, DRUGU, EMBASE, IMSDRUGNEWS,
IMSRESEARCH, IPA, MEDLINE, PHAR, PROMT, PROUSDDR, TOXCENTER, USAN,
USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

187 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
188 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e8

L16 1 99614-02-5/RN

=> d

L16 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 99614-02-5 REGISTRY

ED Entered STN: 04 Jan 1986

CN 4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1,2,3,4-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-9H-carbazol-4-one

CN GR 38032

CN GR 38032X

CN Ondansetron

CN Zofran

CN Zophren

CN Zudan

FS 3D CONCORD

DR 808754-64-5, 108303-49-7, 116002-70-1

MF C18 H19 N3 O


CI COM

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHM, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, NIOSHTIC, PATDPASPC, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1226 REFERENCES IN FILE CA (1907 TO DATE)

18 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1230 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e9

L17 1 102141-11-7/RN

=> d


L17 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 102141-11-7 REGISTRY

ED Entered STN: 17 May 1986

CN Benzenemethanol, 3-chloro- α -[(1R)-1-[(1,1-dimethylethyl)amino]ethyl]-
 , (α S)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Benzenemethanol, 3-chloro- α -[1-[(1,1-dimethylethyl)amino]ethyl]-,
 (R*,S*)-(+)-
 FS STEREOSEARCH
 MF C13 H20 Cl N O
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
 5 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> s e10

L18 1 102141-12-8/RN

=> d

L18 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 102141-12-8 REGISTRY
 ED Entered STN: 17 May 1986
 CN Benzenemethanol, 3-chloro- α -[(1S)-1-[(1,1-dimethylethyl)amino]ethyl]-
 , (α S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C13 H20 Cl N O
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1907 TO DATE)
 8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e11

L19 1 106083-71-0/RN

=> d

L19 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 106083-71-0 REGISTRY

ED Entered STN: 10 Jan 1987

CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, hydrochloride,
(2S,3S)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, hydrochloride,
[S-(R*,R*)]-

OTHER NAMES:

CN BW 306U

CN GW 353162A

CN Radafaxine hydrochloride


FS STEREOSEARCH

MF C13 H18 Cl N O2 . Cl H

SR CA

LC STN Files: ADISINSIGHT, BIOSIS, CA, CAPLUS, DDFU, DRUGU, EMBASE,
IMSDRUGNEWS, IMSRESEARCH, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
CRN (192374-14-4)

Absolute stereochemistry. Rotation (+).



● HCl

14 REFERENCES IN FILE CA (1907 TO DATE)

14 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s el2

L20 1 124-68-5/RN

=> d

L20 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 124-68-5 REGISTRY

ED Entered STN: 16 Nov 1984

CN 1-Propanol, 2-amino-2-methyl- (8CI, 9CI) (CA INDEX NAME)

OTHER NAMES:

CN β -Aminoisobutanol

CN 1,1-Dimethyl-2-hydroxyethylamine

CN 2,2-Dimethylethanolamine

CN 2-Amino-1-hydroxy-2-methylpropane


CN 2-Amino-2,2-dimethylethanol

CN 2-Amino-2-methyl-1-propanol

CN 2-Amino-2-methylpropanol

CN 2-Aminoisobutanol

CN 2-Hydroxy-1,1-dimethylethylamine
 CN 2-Hydroxymethyl-2-propylamine
 CN 2-Methyl-2-amino-1-propanol
 CN 2-Methyl-2-aminopropanol
 CN AMP
 CN AMP (thinner)
 CN AMP 75
 CN AMP 90
 CN AMP 90 (amine)
 CN AMP 95
 CN AMP Regular
 CN Corrguard 75
 CN Hydroxy-tert-butylamine
 CN Isobutanol-2-amine
 CN KV 5088
 CN NSC 441
 CN Pamabron
 FS 3D CONCORD
 DR 189832-99-3
 MF C4 H11 N O
 CI COM
 LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA,
 CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST,
 CHEMSAFE, CIN, CSCHEM, CSNB, DETHERM*, EMBASE, GMELIN*, HODOC*, HSDB*,
 IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PIRA,
 PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL,
 VTB
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2897 REFERENCES IN FILE CA (1907 TO DATE)
 144 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 2902 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 16 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


=> s e13

L21 1 153365-82-3/RN

=> d

L21 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 153365-82-3 REGISTRY
 ED Entered STN: 02 Mar 1994
 CN Benzenemethanol, 3-chloro- α -[(1R)-1-[(1,1-dimethylethyl)amino]ethyl]-
 , (α R)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C13 H20 Cl N O
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e14

L22 1 18162-48-6/RN

=> d

L22 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 18162-48-6 REGISTRY

ED Entered STN: 16 Nov 1984

CN Silane, chloro(1,1-dimethylethyl)dimethyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Silane, chloro-tert-butyltrimethyl- (8CI)

OTHER NAMES:

CN (1,1-Dimethylethyl)dimethylsilyl chloride

CN Chloro(1,1-dimethylethyl)dimethylsilane

CN Chloro-tert-butyltrimethylsilane

CN Chlorodimethyl-tert-butylsilane

CN Dimethyl(1,1-dimethylethyl)chlorosilane

CN Dimethyl-tert-butylchlorosilane

CN Dimethyl-tert-butylsilyl chloride

CN t-Butyltrimethylchlorosilane

CN TBDMS chloride

CN TBDMS-Cl

CN tert-Butylchlorodimethylsilane

CN tert-Butyltrimethylchlorosilane

CN tert-Butyltrimethylsilyl chloride

FS 3D CONCORD

DR 132560-73-7, 187979-91-5


MF C6 H15 Cl Si

LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHM, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: EINECS**, NDSL**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4127 REFERENCES IN FILE CA (1907 TO DATE)
37 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
4137 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


=> s e15

L23 1 192374-14-4/RN

=> d

L23 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 192374-14-4 REGISTRY
ED Entered STN: 08 Aug 1997
CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, (2S,3S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, (2S-cis)-
OTHER NAMES:
CN (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol
CN GW 353162
CN Radafaxine
FS STEREOSEARCH
MF C13 H18 Cl N O2
CI COM
SR CA
LC STN Files: ADISINSIGHT, BIOSIS, CA, CAPLUS, CASREACT, EMBASE, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

17 REFERENCES IN FILE CA (1907 TO DATE)
17 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e16


L24 1 192374-15-5/RN

=> d

L24 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 192374-15-5 REGISTRY
ED Entered STN: 08 Aug 1997
CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, (2R,3R)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, (2R-cis)-
OTHER NAMES:
CN (-)-(2R,3R)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol
FS STEREOSEARCH

MF C13 H18 Cl N O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (-).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1907 TO DATE)
12 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d

L24 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 192374-15-5 REGISTRY
ED Entered STN: 08 Aug 1997
CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, (2R,3R)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, (2R-cis)-
OTHER NAMES:
CN (-)-(2R,3R)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol
FS STEREOSEARCH
MF C13 H18 Cl N O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1907 TO DATE)
12 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> s e17

L25 1 287477-53-6/RN

=> d

L25 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 287477-53-6 REGISTRY
ED Entered STN: 28 Aug 2000
CN 1-Propanone, 1-(3-chlorophenyl)-2-hydroxy-, (2S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C9 H9 Cl O2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1907 TO DATE)
8 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> s e18

L26 1 291275-45-1/RN

=> d

L26 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 291275-45-1 REGISTRY
ED Entered STN: 27 Sep 2000
CN Silane, [[[1Z)-1-(3-chlorophenyl)-1-propenyl]oxy](1,1-dimethylethyl)dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H23 Cl O Si
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> s e19

L27 1 291275-46-2/RN

=> d

L27 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 291275-46-2 REGISTRY
ED Entered STN: 27 Sep 2000
CN 1-Propanone, 1-(3-chlorophenyl)-2-hydroxy-, (2R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C9 H9 Cl O2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> s e20

L28 1 292055-71-1/RN

=> d

L28 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 292055-71-1 REGISTRY
ED Entered STN: 02 Oct 2000
CN Benzenemethanol, 3-chloro- α -[(1S)-1-[(1,1-dimethylethyl)amino]ethyl]-, hydrochloride, (α S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H20 Cl N O . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (102141-12-8)

Absolute stereochemistry. Rotation (+).



● HCl

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e21

L29 1 292055-72-2/RN

=> d

L29 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 292055-72-2 REGISTRY

ED Entered STN: 02 Oct 2000

CN Benzenemethanol, 3-chloro- α -[(1S)-1-[(1,1-dimethylethyl)amino]ethyl]-, (α R)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C13 H20 Cl N O

CI COM

SR CA

LC STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e22

L30 1 31677-93-7/RN

=> d

L30 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 31677-93-7 REGISTRY

ED Entered STN: 16 Nov 1984

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, hydrochloride, (\pm)-

CN Propiophenone, 2-(tert-butylamino)-3'-chloro-, hydrochloride, (\pm)- (8CI)

OTHER NAMES:

CN α -(tert-Butylamino)-m-chloropropiophenone hydrochloride

CN Bupropion hydrochloride

CN DL- α -t-Butylamino-3-chloropropiophenone hydrochloride

CN m-Chloro- α -tert-butylaminopropiophenone hydrochloride

CN NSC 315851

CN Wellbatrin

CN Wellbutrin

CN Zyban


CN Zyban (pharmaceutical)

DR 34841-36-6

MF C13 H18 Cl N O . Cl H

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN,
 CSChem, DIOGENES, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH,
 IMSPATENTS, IMSRESEARCH, IPA, MRCK*, MSDS-OHS, PATDPASPC, PHAR, PROMT,
 PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)
 CRN (34911-55-2)



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

169 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 169 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e23

L31 1 32634-66-5/RN

=> d

L31 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 32634-66-5 REGISTRY

ED Entered STN: 16 Nov 1984

CN Butanedioic acid, 2,3-bis[(4-methylbenzoyl)oxy]-, [R-(R*,R*)]- (9CI) (CA
 INDEX NAME)

OTHER NAMES:

CN (-)-Di-O,O'-p-toluoyltartaric acid

CN (-)-Di-O-p-toluoyl-L-tartaric acid

CN (-)-Di-p-toluoyltartaric acid

CN (-)-O,O-Di-p-toluoyltartaric acid

CN (2R,3R)-(-)-Di(p-toluoyl) tartaric acid

CN (R,R)-O,O'-Di-p-toluoyltartaric acid

CN Di-4-toluoyl-L-tartaric acid

CN Di-p-Toluoyl-d-tartaric acid

CN Di-p-toluoyl-L-tartaric acid

CN L-Di-O,O'-p-toluoyltartaric acid

CN Tartaric acid, di-p-toluate

AR 100168-11-4

FS STEREOSEARCH

DR 131774-02-2, 64101-05-9, 104695-67-2, 76210-55-4, 79780-69-1, 47375-16-6,
 47591-89-9

MF C20 H18 O8


CI COM

LC STN Files: AGRICOLA, BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS,
 CHEMINFORMRX, CHEMLIST, CSChem, IFICDB, IFIPAT, IFIUDB, IPA, MSDS-OHS,
 SPECINFO, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)

Other Sources: EINECS**, NDSL**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

186 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

186 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e24

L32 1 34841-35-5/RN

=> d

L32 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 34841-35-5 REGISTRY

ED Entered STN: 16 Nov 1984

CN 1-Propanone, 1-(3-chlorophenyl)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Propiophenone, 3'-chloro- (6CI, 7CI)

OTHER NAMES:

CN 1-(3-Chlorophenyl)-1-propanone

CN 3-Chlorophenyl ethyl ketone

CN m-Chloropropiophenone


FS 3D CONCORD

MF C9 H9 Cl O

LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHM, IFICDB, IFIPAT, IFIUDB, MSDS-OHS, PROMT, PS, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

61 REFERENCES IN FILE CA (1907 TO DATE)

61 REFERENCES IN FILE CAPLUS (1907 TO DATE)

9 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s e25

L33 1 34911-51-8/RN

=> d

L33 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 34911-51-8 REGISTRY

ED Entered STN: 16 Nov 1984

CN 1-Propanone, 2-bromo-1-(3-chlorophenyl)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Propiophenone, 2-bromo-3'-chloro- (7CI)

OTHER NAMES:

CN α -Bromo-3-chloropropiophenone

CN α -Bromo-m-chloropropiophenone

CN 2-Bromo-3'-chloropropiophenone

FS 3D CONCORD

DR 92821-81-3


MF C9 H8 Br Cl O

LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST,
IFICDB, IFIPAT, IFIUDB, PS, TOXCENTER, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

29 REFERENCES IN FILE CA (1907 TO DATE)

29 REFERENCES IN FILE CAPLUS (1907 TO DATE)

3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s e26

L34 1 357399-43-0/RN

=> d

L34 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 357399-43-0 REGISTRY

ED Entered STN: 19 Sep 2001

CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl- (9CI) (CA INDEX NAME)

OTHER NAMES:


CN 2-Hydroxy-2-(3-chlorophenyl)-3,5,5-trimethylmorpholine

FS 3D CONCORD

MF C13 H18 Cl N O2

SR CA

LC STN Files: CA, CAPLUS, CHEMCATS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e27

L35 1 357399-44-1/RN

=> d

L35 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN **357399-44-1** REGISTRY

ED Entered STN: 19 Sep 2001

CN Butanedioic acid, 2,3-bis[(4-methylbenzoyl)oxy]-, (2R,3R)-, compd. with
(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol (1:1) (9CI) (CA
INDEX NAME)

OTHER CA INDEX NAMES:

CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, (2S,3S)-,
(2R,3R)-2,3-bis[(4-methylbenzoyl)oxy]butanedioate (1:1) (salt) (9CI)

FS STEREOSEARCH

MF C20 H18 O8 . C13 H18 Cl N O2

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 192374-14-4

CMF C13 H18 Cl N O2

Absolute stereochemistry. Rotation (+).




CM 2

CRN 32634-66-5

CMF C20 H18 O8

Absolute stereochemistry. Rotation (-).



4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> s e28

L36 1 357628-59-2/RN

=> d

L36 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 357628-59-2 REGISTRY
ED Entered STN: 20 Sep 2001
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(2-hydroxy-1,1-dimethylethyl)amino]-,
(2R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H18 Cl N O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e29


L37 1 357628-60-5/RN

=> d

L37 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 357628-60-5 REGISTRY
ED Entered STN: 20 Sep 2001
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(2-hydroxy-1,1-dimethylethyl)amino]-,
(2S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H18 Cl N O2
CI COM

SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> s e30

L38 1 357628-62-7/RN

=> d

L38 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 357628-62-7 REGISTRY
ED Entered STN: 20 Sep 2001
CN Benzenemethanol, 3-chloro- α -[(1S)-1-[(1,1-dimethylethyl)amino]ethyl]-
, hydrochloride, (α R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H20 Cl N O . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (292055-72-2)

Absolute stereochemistry.



● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e31

L39 1 357628-63-8/RN

=> d


L39 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 357628-63-8 REGISTRY
 ED Entered STN: 20 Sep 2001
 CN Benzenemethanol, 3-chloro- α -[(1R)-1-[(1,1-dimethylethyl)amino]ethyl]-
 , (α R)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA
 INDEX NAME)
 FS STEREOSEARCH
 MF C13 H20 Cl N O . C4 H6 O6
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 153365-82-3
 CMF C13 H20 Cl N O


Absolute stereochemistry. Rotation (-).



CM 2

CRN 87-69-4
 CMF C4 H6 O6

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e32

L40 1 357628-64-9/RN


=> d

L40 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 357628-64-9 REGISTRY
 ED Entered STN: 20 Sep 2001
 CN Benzenemethanol, 3-chloro- α -[(1S)-1-[(1,1-dimethylethyl)amino]ethyl]-
 , (α S)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA
 INDEX NAME)
 FS STEREOSEARCH
 MF C13 H20 Cl N O . C4 H6 O6
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 102141-12-8
CMF C13 H20 Cl N O


Absolute stereochemistry. Rotation (+).



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> s e33

L41 1 357637-16-2/RN

=> d

L41 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 357637-16-2 REGISTRY
ED Entered STN: 20 Sep 2001
CN Benzenemethanol, 3-chloro- α -[(1R)-1-[(1,1-dimethylethyl)amino]ethyl]-
, hydrochloride, (α S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H20 Cl N O . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (102141-11-7)

Absolute stereochemistry. Rotation (+).



● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> s e34

L42 1 357637-18-4/RN

=> d

L42 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 357637-18-4 REGISTRY
ED Entered STN: 20 Sep 2001
CN Benzenemethanol, 3-chloro- α -[(1R)-1-[(1,1-dimethylethyl)amino]ethyl]-
, hydrochloride, (α R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H20 Cl N O . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (153365-82-3)

Absolute stereochemistry. Rotation (-).



● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e35

L43 1 386210-39-5/RN


=> d

L43 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 386210-39-5 REGISTRY
ED Entered STN: 24 Jan 2002
CN Butanedioic acid, 2,3-bis[(4-methylbenzoyl)oxy]-, (2R,3R)-, compd. with
(2R,3R)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol (1:1) (9CI) (CA
INDEX NAME)
FS STEREOSEARCH
MF C20 H18 O8 . C13 H18 Cl N O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 192374-15-5
CMF C13 H18 Cl N O2

Absolute stereochemistry. Rotation (-).




CM 2

CRN 32634-66-5

CMF C20 H18 O8

Absolute stereochemistry. Rotation (-).



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e44

L44 1 87-69-4/RN

=> s e36

L45 1 386210-40-8/RN

=> d

L45 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN **386210-40-8** REGISTRY

ED Entered STN: 24 Jan 2002

CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, (2R,3S)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C13 H18 Cl N O2

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> s e37

L46 1 386210-41-9/RN

=> d

L46 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **386210-41-9** REGISTRY
ED Entered STN: 24 Jan 2002
CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, (2S,3R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H18 Cl N O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> s e38

L47 1 50-67-9/RN

=> d

L47 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **50-67-9** REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Indol-5-ol, 3-(2-aminoethyl)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Indol-5-ol, 3-(2-aminoethyl)- (6CI, 8CI)
OTHER NAMES:
CN 3-(β -Aminoethyl)-5-hydroxyindole
CN 3-(2-Aminoethyl)-1H-indol-5-ol
CN 3-(2-Aminoethyl)indol-5-ol
CN 5-HT
CN 5-HTA
CN 5-Hydroxy-3-(β -aminoethyl)indole
CN 5-Hydroxyltryptamine
CN 5-Hydroxytryptamine
CN 5-Hydroxytryptamine
CN Antemovis
CN DS substance
CN Enteramin

CN Enteramine
 CN Serotonin
 CN Substance DS
 CN Thrombocytin
 CN Thrombotonin
 CN Tryptamine, 5-hydroxy-
 FS 3D CONCORD
 DR 33361-47-6
 MF C10 H12 N2 O
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS,
 BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB,
 CEN, CHEMCATS, CHEMLIST, CIN, CSCHM, CSNB, DDFU, DRUGU, EMBASE, IFICDB,
 IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PROMT, RTECS*,
 SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


51386 REFERENCES IN FILE CA (1907 TO DATE)
 303 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 51414 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 205 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s e45

L48 1 92264-81-8/RN

=> d

L48 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 92264-81-8 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 1-Propanone, 1-(3-chlorophenyl)-2-[(2-hydroxy-1,1-dimethylethyl)amino]-
 (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 DR 82793-84-8
 MF C13 H18 Cl N O2
 CI COM
 LC STN Files: CA, CAPLUS, CHEMCATS, CSCHM, MEDLINE, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

22 REFERENCES IN FILE CA (1907 TO DATE)
22 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e3 or e9 or e10 or e13 or e20-22 or e30-e34
L49 12 34911-55-2/RN OR 102141-11-7/RN OR 102141-12-8/RN OR 153365-82-3
/RN OR (292055-71-1/RN OR 292055-72-2/RN OR 31677-93-7/RN) OR
(357628-62-7/RN OR 357628-63-8/RN OR 357628-64-9/RN OR 357637-16
-2/RN OR 357637-18-4/RN)

=> fil uspatful , caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
92.76	110.47

FULL ESTIMATED COST

FILE 'USPATFULL' ENTERED AT 17:30:20 ON 15 OCT 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 17:30:20 ON 15 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 149
L50 293 FILE USPATFULL
L51 938 FILE CAPLUS

TOTAL FOR ALL FILES
L52 1231 L49

=> d 151 925-938 hit, hitstr, ibib

L51 ANSWER 925 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN
AB The ability of antidepressant drugs, electroconvulsive treatment (ECT) or LiCl to modify prolactin [9002-62-4] secretion in the rat was studied. Chlorimipramine [303-49-1], citalopram [59729-33-8], fluoxetine [54910-89-3], imipramine [50-49-7], and zimelidine [56775-88-3] potentiated the low dose 5-hydroxytryptophan (5-HTP)-induced increase in prolactin secretion, suggesting inhibition of 5-HT [50-67-9] uptake by these drugs. Amitriptyline [50-48-6], doxepin [1668-19-5], iprindole [5560-72-5], mianserin [24219-97-4], and trazodone [19794-93-5] inhibited the prolactin-stimulating effects of high doses of 5-HTP and quipazine, suggesting that these drugs have 5-HT receptor blocking properties. Tandamine [42408-80-0] inhibited only 5-HTP-induced increase in prolactin secretion. Chronic administration of imipramine potentiated the effect of low dose 5-HTP significantly more than an acute dose. Amitriptyline produced similar inhibition of the 5-HTP-induced increase in prolactin secretion after both acute and chronic administration. The ability of bupropion [34911-55-2] and mazindol [22232-71-9] to inhibit α -methylparatyrosine-induced prolactin secretion, and of nomifensine to inhibit reserpine-induced prolactin secretion, is consistent with other evidence that these agents are indirect dopamine (DA) [51-61-6] agonists. Desipramine [50-47-5], acutely, had no effect on any of the above paradigms, but after chronic administration, potentiated the effect of low dose 5-HTP on prolactin secretion. Nortriptyline [72-69-5] had no effect on prolactin secretion after acute or chronic treatment. ECT for 10 days did not affect the ability of a 5-HT agonist or d-amphetamine to modify prolactin secretion. However, chronic, but not acute, treatment with LiCl markedly enhanced the prolactin response to 5-HT agonists and reserpine while shifting the dose response curve for d-amphetamine and apomorphine to the right. These results are discussed in light of current theories of the role of 5-HT and


DA in depression.

IT 50-47-5 50-48-6 50-49-7 72-69-5 303-49-1 1668-19-5 5560-72-5
 7447-41-8, biological studies 19794-93-5 22232-71-9 24219-97-4
34911-55-2 42408-80-0 54910-89-3 56775-88-3 59729-33-8
 RL: BIOL (Biological study)
 (prolactin of blood serum response to, dopamine and hydroxytryptamine
 in relation to)

IT **34911-55-2**
 RL: BIOL (Biological study)
 (prolactin of blood serum response to, dopamine and hydroxytryptamine
 in relation to)

RN 34911-55-2 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA
 INDEX NAME)



ACCESSION NUMBER: 1981:202641 CAPLUS

DOCUMENT NUMBER: 94:202641

TITLE: Effect of antidepressants, lithium and
 electroconvulsive treatment on rat serum prolactin
 levels

AUTHOR(S): Meltzer, H. Y.; Simonovic, M.; Sturgeon, R. D.; Fang,
 V. S.

CORPORATE SOURCE: Pritzker Sch. Med., Univ. Chicago, Chicago, IL, USA

SOURCE: Acta Psychiatrica Scandinavica, Supplementum (1981),
 290(Recent Adv. Treat. Depression), 100-21
 CODEN: ASSUA6; ISSN: 0065-1591

DOCUMENT TYPE: Journal

LANGUAGE: English


L51 ANSWER 926 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN

IT **34911-55-2**
 RL: BIOL (Biological study)
 (determination by radioimmunoassay and pharmacokinetics of)

IT **34911-55-2**
 RL: BIOL (Biological study)
 (determination by radioimmunoassay and pharmacokinetics of)

RN 34911-55-2 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA
 INDEX NAME)



ACCESSION NUMBER: 1981:202441 CAPLUS

DOCUMENT NUMBER: 94:202441

TITLE: Studies on the pharmacology and disposition of
 bupropion in rats and mice, using radioimmunoassay

AUTHOR(S): Butz, Robert
CORPORATE SOURCE: Duke Univ., Durham, NC, USA
SOURCE: (1980) 160 pp. Avail.: Univ. Microfilms Int., Order No. 8105653
From: Diss. Abstr. Int. B 1981, 41(9), 3405
DOCUMENT TYPE: Dissertation
LANGUAGE: English

L51 ANSWER 927 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN

AB The cardiotoxic effects of amitriptyline-HCl (I-HCl) [549-18-8] and imipramine-HCl (II-HCl) [113-52-0] were evaluated by studying their effects on excitable membranes and compared to that of bupropion-HCl (III-HCl) [31677-93-7]. In crayfish giant axon, all antidepressants exhibited local anesthetic-like action by reducing the action potential amplitude and maximum rate of upstroke (dv/dt). The tricyclics were the most potent agents in blocking atrial and papillary muscle excitation; however, III was the least toxic of the compds. tested on the cardiac tissue. The quinidine-like action of the tricyclics on cardiac-tissue is probably related to the antiarrhythmic and/or cardiotoxic manifestation in man and animals.

IT 113-52-0 549-18-8 31677-93-7


RL: BIOL (Biological study)
(heart toxicity from)

IT 31677-93-7

RL: BIOL (Biological study)
(heart toxicity from)

RN 31677-93-7 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

ACCESSION NUMBER: 1981:76627 CAPLUS
DOCUMENT NUMBER: 94:76627
TITLE: Electrophysiological effects of antidepressants on mammalian hearts and crayfish giant axon
AUTHOR(S): Wang, Ching M.; Parker, Charles H., Jr.; Maxwell, Robert A.
CORPORATE SOURCE: Dep. Pharmacol., Wellcome Res. Lab., Research Triangle Park, NC, USA
SOURCE: Journal of Cardiovascular Pharmacology (1980), 3(1), 101-12
CODEN: JCPCDT; ISSN: 0160-2446
DOCUMENT TYPE: Journal
LANGUAGE: English

L51 ANSWER 928 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN

AB Bupropion-HCl (BW 323U; Wellbutrin) (I) [31677-93-7], a novel compound with antidepressant effects in man, reduced immobility in an exptl. helplessness forced swimming antidepressant test in rats as did imipramine and amitriptyline. Higher doses produced elevated locomotor activity in an automated open field and produced stereotyped sniffing which was

contrasted with apomorphine. When bupropion or desmethylinipramine was given before intracisternal injections of 6-hydroxydopamine, bupropion produced a dose-related selective antagonism of the destruction of dopamine [51-61-6] neurons, while under the same conditions, desmethylinipramine produced a dose-related selective antagonism of the destruction of noradrenergic neurons. Studies in which the dose of bupropion and the dose 6-hydroxydopamine were varied revealed that a dose-related selective antagonism of dopamine depletion by 6-hydroxydopamine occurred when doses .ltorsim. 50 mg/kg, i.p. of bupropion were administered. Some antagonism of norepinephrine depletion also occurred at 100 mg bupropion/kg, i.p. Bupropion also selectively reversed the dopamine depletion produced by α -methyl-m-tyrosine, a finding which is consistent with the view that bupropion is a dopamine uptake inhibitor in vivo. The importance of dopamine systems for the behavioral effects of bupropion were also studied. When the locomotor stimulant effects of bupropion were tested in rats with chronic destruction of dopamine neurons produced by 6-hydroxydopamine, bupropion failed to elevate locomotor activity. Rats treated with procedures using 6-hydroxydopamine to produce relatively selective norepinephrine depletions responded to bupropion with locomotor activity stimulation like controls. Rats with similar depletions of either dopamine or norepinephrine were also tested for the ability of low doses of bupropion to reduce immobility in the exptl. helplessness forced swim antidepressant test. Prior destruction of dopamine neurons prevented activity of bupropion in this test. Results indicate that bupropion is a selective dopamine uptake inhibitor in vivo and that dopaminergic systems play an important role in its central nervous system pharmacol.

IT 31677-93-7

RL: BIOL (Biological study)

(behavior response to, dopamine uptake inhibition in relation to)


IT 31677-93-7

RL: BIOL (Biological study)

(behavior response to, dopamine uptake inhibition in relation to)

RN 31677-93-7 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

ACCESSION NUMBER:	1980:597747 CAPLUS
DOCUMENT NUMBER:	93:197747
TITLE:	Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo
AUTHOR(S):	Cooper, Barrett R.; Hester, Teresa J.; Maxwell, Robert A.
CORPORATE SOURCE:	Dep. Pharmacol., Burroughs Wellcome Co., Research Triangle Park, NC, USA
SOURCE:	Journal of Pharmacology and Experimental Therapeutics (1980), 215(1), 127-34
DOCUMENT TYPE:	CODEN: JPETAB; ISSN: 0022-3565 Journal

LANGUAGE: English

L51 ANSWER 929 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN

AB Tricyclic antidepressants (amitriptyline [50-48-6], chlorimipramine [303-49-1], desmethylinipramine [50-47-5], and nortriptyline [72-69-5], all 10 mg/kg i.p.) and monoamine oxidase inhibitors (nialamide [51-12-7] and tranylcypromine [155-09-9], 40 and 5 mg/kg, resp.) given twice daily for 16 days reduced the number of β -adrenergic receptor binding sites in rat cerebral cortex homogenates, as determined from dihydroalprenolol-3H binding. Iprindole [5560-72-5] and bupropion [34911-55-2] (10 and 20-80 mg/kg, resp.) had the same effect. However, mianserin [24219-97-4] (10 mg/kg) and 11 other psychoactive drugs had no effect. Thus, drug-treatment-induced lowering of dihydroalprenolol-3H binding sites in cerebral cortex apparently has use as a preclin. test for antidepressant drugs.

IT 50-47-5 50-48-6 51-12-7 72-69-5 155-09-9 303-49-1 5560-72-5
34911-55-2

RL: BIOL (Biological study)

(β -adrenergic receptor binding sites of brain reduction by)


IT 34911-55-2

RL: BIOL (Biological study)

(β -adrenergic receptor binding sites of brain reduction by)

RN 34911-55-2 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 1980:488704 CAPLUS

DOCUMENT NUMBER: 93:88704

TITLE: The effect of psychoactive drugs on beta-adrenergic receptor binding sites in rat brain

AUTHOR(S): Sellinger-Barnette, Mary M.; Mendels, J.; Frazer, A.

CORPORATE SOURCE: VA Hosp., Univ. Pennsylvania Sch. Med., Philadelphia, PA, USA

SOURCE: Neuropharmacology (1980), 19(5), 447-54

CODEN: NEPHBW; ISSN: 0028-3908

DOCUMENT TYPE: Journal


LANGUAGE: English

L51 ANSWER 930 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN

AB Various doses of bupropion-HCl (I) [31677-93-7] (Wellbatrin) (5, 10, and 20 mg/kg) were employed as cues in a 2-lever operant discrimination from saline control injections in rats on an FR10 schedule of food reinforcement. Subjects reached and maintained a high level of discrimination in the 0 vs 20 mg I/kg stimulus condition but not at the lower doses. In generalization testing, the following compds. produced dose-related responding on the I lever: viloxazine, nomifensine, caffeine, d-amphetamine, cocaine, methylphenidate, and benzyloperazine. Drugs that failed to show dose-related generalization included phenethylamine, thyrotropin-releasing hormone, imipramine, nortriptyline, amitriptyline, desipramine, mianserin, chlordiazepoxide, diazepam, scopolamine, phenobarbital, and morphine. With the important exception of viloxazine, the generalization profile of I seems to reflect its previously reported locomotor stimulant effects in the rat rather than its antidepressant activity and suggests that species differences exist between man and rat

with regard to the pharmacol. activity of this new antidepressant.

IT **31677-93-7**
RL: BIOL (Biological study)
(behavior response to, as discriminative stimulus for antidepressants)
IT **31677-93-7**
RL: BIOL (Biological study)
(behavior response to, as discriminative stimulus for antidepressants)
RN 31677-93-7 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-,
hydrochloride (9CI) (CA INDEX NAME)



● HCl


ACCESSION NUMBER: 1980:174443 CAPLUS
DOCUMENT NUMBER: 92:174443
TITLE: Stimulus properties of antidepressants in the rat
AUTHOR(S): Jones, Catherine N.; Howard, James L.; McBennett, S. Teresa
CORPORATE SOURCE: Dep. Pharmacol., Wellcome Res. Lab., Research Triangle Park, NC, 27709, USA
SOURCE: Psychopharmacology (Berlin, Germany) (1980), 67(2), 111-18
CODEN: PSCHDL; ISSN: 0033-3158
DOCUMENT TYPE: Journal
LANGUAGE: English

L51 ANSWER 931 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN

AB Bupropion-HCl (I) [**31677-93-7**], a non-tricyclic compound with antidepressant effects in man, was evaluated for effects on plasma prolactin (PRL) [9002-62-4] and growth hormone (GH) [9002-72-6] levels in normal human subjects, and for effects on plasma PRL levels in a series of pharmacol. studies in normal rats. Single oral doses of 50, 100 or 200 mg of I given to male and female subjects produced a marked suppression (80% decrease) of PRL. Incomplete PRL recovery was observed at the end of 24 h. One hour after I administration there was a +0.56 correlation of percent decrease in PRL levels with I plasma levels. GH showed only small and erratic changes in plasma levels at 1-4 h post-dose. In the rat, single I doses of 25 mg/kg, i.p., failed to lower basal PRL levels. I, however, decreased PRL in rats in which plasma PRL was elevated by pretreatment with α -methyltyrosine, 5-hydroxytryptophan, or quipazine. However I did not counteract the PRL-elevating effect of haloperidol. Results in man and rat are consistent with the view that I has significant dopamine mimetic properties.

IT **31677-93-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(growth hormone and prolactin of blood plasma response to)
IT **31677-93-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(growth hormone and prolactin of blood plasma response to)
RN 31677-93-7 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-,
hydrochloride (9CI) (CA INDEX NAME)



● HCl

ACCESSION NUMBER: 1980:34480 CAPLUS
DOCUMENT NUMBER: 92:34480
TITLE: Influence of bupropion hydrochloride (Wellbatrin), a novel antidepressant, on plasma levels of prolactin and growth hormone in man and rat
AUTHOR(S): Stern, W. C.; Rogers, J.; Fang, V.; Meltzer, H.
CORPORATE SOURCE: Dep. Clin. Res., Burroughs Wellcome Co., Research Triangle Park, NC, USA
SOURCE: Life Sciences (1979), 25(20), 1717-24
CODEN: LIFSAK; ISSN: 0024-3205
DOCUMENT TYPE: Journal
LANGUAGE: English

L51 ANSWER 932 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN


AB In conscious unrestrained rats, bupropion (I) [34911-55-2] (5 and 10 mg/kg, s.c.) was similar to dexamphetamine and nomifensine in inducing EEG arousal which was reduced or blocked by pretreatment with pimozide (1.7 mg/kg), whereas desipramine (5 mg/kg)-induced arousal was not reduced. I, in contrast to desipramine and nomifensine, prevented 6-hydroxydopamine (125 µg/10 µL)-induced depletion of brain dopamine (II) [51-61-6] but was ineffective against noradrenaline (III) depletion. Dexamphetamine was effective against both II and III depletion. In rat striatal II-sensitive adenylate cyclase preparation, I (100µM) had no effect on the production of either basal or II-stimulated cyclic AMP. Thus, II is involved in at least some of the central actions of I. I may inhibit II uptake in vivo in the rat.

IT 34911-55-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(dopamine of brain response to, antidepressant activity in relation to)

IT 34911-55-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(dopamine of brain response to, antidepressant activity in relation to)

RN 34911-55-2 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 1980:329 CAPLUS
DOCUMENT NUMBER: 92:329
TITLE: The involvement of dopamine in the central actions of bupropion, a new antidepressant
AUTHOR(S): Canning, H.; Goff, D.; Leach, M. J.; Miller, A. A.; Tateson, J. E.; Wheatley, P. L.
CORPORATE SOURCE: Pharmacol. Lab., Wellcome Res. Lab., Beckenham, UK
SOURCE: British Journal of Pharmacology (1979), 66(1), 104P-105P
CODEN: BJPCBM; ISSN: 0007-1188
DOCUMENT TYPE: Journal
LANGUAGE: English

L51 ANSWER 933 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN


AB Bupropion-HCl (I) [31677-93-7] (50 and 100 mg, orally) given to volunteers differed from both amitriptyline (25 mg) and dexamphetamine sulfate (10 mg) in effects on performance tests, autonomic variables, EEG changes, and subjective effects. However, I failed to differ from lactose on any of the measures of performance tested. I was devoid of stimulant and sedative properties. I had no cardiovascular or anticholinergic effects and appeared to be an effective potential antidepressant.

IT 31677-93-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of)

IT 31677-93-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of)

RN 31677-93-7 CAPLUS


CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

ACCESSION NUMBER: 1979:483503 CAPLUS
DOCUMENT NUMBER: 91:83503
TITLE: A comparison of bupropion hydrochloride with dexamphetamine and amitriptyline in healthy subjects
AUTHOR(S): Peck, A. W.; Bye, C. E.; Clubley, M.; Henson, T.; Riddington, C.
CORPORATE SOURCE: Dep. Clin. Pharmacol., Wellcome Res. Lab., Beckenham/Kent, UK
SOURCE: British Journal of Clinical Pharmacology (1979), 7(5), 469-78
CODEN: BCPHBM; ISSN: 0306-5251
DOCUMENT TYPE: Journal
LANGUAGE: English


L51 ANSWER 934 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN
 AB Rats were successfully trained to discriminate between the injection of 0 and 20 mg/kg of Wellbatrin (bupropion-HCl) (I) [31677-93-7], a new antidepressant. The discrimination was observed for over 10 mos. Poor generalization between the I cue and those of 4 tricyclic antidepressants, chlordiazepoxide-HCl [438-41-5] and other psychotropic drugs was observed. However, stimulus generalization to 4 classes of drugs producing increases in locomotor activity was demonstrated. Thus, the stimulus properties of I appear to reflect most strongly the locomotor stimulant effects. These data also do not give much support to the idea that antidepressants manifest a common stimulus property in rats.
 IT **31677-93-7**
 RL: BIOL (Biological study)
 (discriminative stimulus properties of, antidepressants in relation to)
 IT **31677-93-7**
 RL: BIOL (Biological study)
 (discriminative stimulus properties of, antidepressants in relation to)
 RN 31677-93-7 CAPLUS
 CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

ACCESSION NUMBER: 1979:432788 CAPLUS
 DOCUMENT NUMBER: 91:32788
 TITLE: Discriminative stimulus properties of antidepressants
 AUTHOR(S): Howard, J. L.; Jones, C. N.; McBennett, S. T.
 CORPORATE SOURCE: Wellcome Res. Lab., Dep. Pharmacol., Triangle Park, NC, 27709, USA
 SOURCE: Stimulus Prop. Drugs: Ten Years Prog., [Proc. Int. Symp. Drugs Discrim. Stimuli], 1st (1978), 157-66.
 Editor(s): Colpaert, Francis C.; Rosecrans, John A.
 Elsevier: Amsterdam, Neth.
 CODEN: 40GXAJ
 DOCUMENT TYPE: Conference
 LANGUAGE: English


L51 ANSWER 935 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN
 IT **31677-93-7**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmacol. of)
 IT **31677-93-7**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmacol. of)
 RN 31677-93-7 CAPLUS
 CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

ACCESSION NUMBER: 1978:182685 CAPLUS
 DOCUMENT NUMBER: 88:182685
 TITLE: Bupropion hydrochloride ((±) α-t-butylamino-3-chloropropiophenone HCl): a novel antidepressant agent
 AUTHOR(S): Soroko, F. E.; Mehta, N. B.; Maxwell, R. A.; Ferris, R. M.; Schroeder, D. H.
 CORPORATE SOURCE: Wellcome Res. Lab., Org. Chem. Med. Biochem. Res., Triangle Park, NC, USA
 SOURCE: Journal of Pharmacy and Pharmacology (1977), 29(12), 767-70
 CODEN: JPPMAB; ISSN: 0022-3573
 DOCUMENT TYPE: Journal
 LANGUAGE: English

L51 ANSWER 936 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN
 IT 455-67-4P **31677-93-7P**
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 IT **31677-93-7P**
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 31677-93-7 CAPLUS
 CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

ACCESSION NUMBER: 1976:164445 CAPLUS
 DOCUMENT NUMBER: 84:164445
 TITLE: α-(tert-Butylamino)-m-chloropropiophenone
 INVENTOR(S): Mehta, Nariman B.; Yeowell, David A.
 PATENT ASSIGNEE(S): Wellcome Foundation Ltd., UK
 SOURCE: Can., 14 pp. Division of Can. 977,777.
 CODEN: CAXXA4
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 977778	A2	19751111	CA 1974-213916	19741115
CA 977777	A1	19751111	CA 1970-99790	19701203
PRIORITY APPLN. INFO.:			CA 1970-99790	A3 19701203
			GB 1969-59231	A 19691204

L51 ANSWER 937 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN
IT 455-67-4P 6084-17-9P **31677-93-7P** 34841-38-8P 34841-40-2P
34841-41-3P **34911-55-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT **31677-93-7P 34911-55-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 31677-93-7 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-,
hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 34911-55-2 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)




ACCESSION NUMBER: 1972:33965 CAPLUS
DOCUMENT NUMBER: 76:33965
TITLE: α-Halopropiophenones
INVENTOR(S): Yeowell, David A.
PATENT ASSIGNEE(S): Wellcome Foundation Ltd.
SOURCE: Ger. Offen., 22 pp. Division of Ger. Offen. 2,059,618.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2064934	A	19711021	DE 1970-2064934	19701203
GB 1340032	A	19731205	GB 1969-59231	19691204


US 3819706	A	19740625	US 1970-93852	19701130
NL 7017687	A	19710608	NL 1970-17687	19701203
NL 172148	B	19830216		
NL 172148	C	19830718		
FR 2081326	A5	19711203	FR 1970-43470	19701203
FR 2081326	B1	19740830		
ZA 7008179	A	19720726	ZA 1970-8179	19701203
AT 302276	B	19721010	AT 1970-10874	19701203
AT 307389	B	19730525	AT 1971-9775	19701203
IL 35781	A1	19730629	IL 1970-35781	19701203
JP 48025179	B4	19730726	JP 1970-106403	19701203
ES 386127	A1	19731216	ES 1970-386127	19701203
NO 131127	B	19741230	NO 1970-4645	19701203
PL 74637	P	19741231	PL 1970-144790	19701203
SE 377933	B	19750804	SE 1970-16354	19701203
DK 134984	B	19770221	DK 1970-6170	19701203
FI 53813	B	19780502	FI 1970-3257	19701203
RO 57979	P	19750315	RO 1970-65195	19701204
CH 569693	A	19751128	CH 1970-18021	19701204
CH 574907	A	19760430	CH 1973-8193	19701204
CS 172338	P	19761229	CS 1970-8205	19701204
CS 209466	P	19811231	CS 1970-1331	19701204
NO 133663	B	19760301	NO 1971-3278	19710902
CS 209466	P	19811231	CS 1972-1331	19720229
US 3885046	A	19750520	US 1973-390845	19730823
DK 7601930	A	19760429	DK 1976-1930	19760429
PRIORITY APPLN. INFO.:			GB 1969-59231	A 19691204
			US 1970-93852	A3 19701130
			DK 1970-6170	A 19701203
			NO 1970-4645	A 19701203
			CS 1970-8205	A3 19701204

L51 ANSWER 938 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN
 IT 455-67-4P 936-59-4P 6084-17-9P **31677-93-7P** 34841-38-8P
 34841-40-2P 34911-51-8P **34911-55-2P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 IT **31677-93-7P 34911-55-2P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 31677-93-7 CAPLUS
 CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-,
 hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 34911-55-2 CAPLUS
 CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 1972:3551 CAPLUS
 DOCUMENT NUMBER: 76:3551
 TITLE: m-Chloro(or fluoro)-α-(tert-butylamino)propiophenone hydrochloride
 INVENTOR(S): Mehta, Nariman B.; Yeowell, David A.
 PATENT ASSIGNEE(S): Wellcome Foundation Ltd.
 SOURCE: Ger. Offen., 29 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2059618	A	19711007	DE 1970-2059618	19701203
DE 2059618	B2	19800710		
DE 2059618	C3	19810416		
GB 1340032	A	19731205	GB 1969-59231	19691204
US 3819706	A	19740625	US 1970-93852	19701130
NL 7017687	A	19710608	NL 1970-17687	19701203
NL 172148	B	19830216		
NL 172148	C	19830718		
FR 2081326	A5	19711203	FR 1970-43470	19701203
FR 2081326	B1	19740830		
ZA 7008179	A	19720726	ZA 1970-8179	19701203
AT 302276	B	19721010	AT 1970-10874	19701203
AT 307389	B	19730525	AT 1971-9775	19701203
IL 35781	A1	19730629	IL 1970-35781	19701203
JP 48025179	B4	19730726	JP 1970-106403	19701203
ES 386127	A1	19731216	ES 1970-386127	19701203
NO 131127	B	19741230	NO 1970-4645	19701203
PL 74637	P	19741231	PL 1970-144790	19701203
SE 377933	B	19750804	SE 1970-16354	19701203
DK 134984	B	19770221	DK 1970-6170	19701203
FI 53813	B	19780502	FI 1970-3257	19701203
RO 57979	P	19750315	RO 1970-65195	19701204
CH 569693	A	19751128	CH 1970-18021	19701204
CH 574907	A	19760430	CH 1973-8193	19701204
CS 172338	P	19761229	CS 1970-8205	19701204
CS 209466	P	19811231	CS 1970-1331	19701204
NO 133663	B	19760301	NO 1971-3278	19710902
CS 209466	P	19811231	CS 1972-1331	19720229
US 3885046	A	19750520	US 1973-390845	19730823
DK 7601930	A	19760429	DK 1976-1930	19760429
PRIORITY APPLN. INFO.:			GB 1969-59231	A 19691204
			US 1970-93852	A3 19701130
			DK 1970-6170	A 19701203
			NO 1970-4645	A 19701203
			CS 1970-8205	A3 19701204

=> s 149 and (treat? or provent/ or prophylac?) and (affective or alcohol or anxiety or (attention deficit) or bipolar or manic or bulimia or (chronic fatigue) or depression or narcolepsy)

'PROVENT/ ' IS NOT A VALID FIELD CODE

For a list of field codes for the current file, enter "HELP SFIELDS"
at an arrow prompt (=>).

=> s 149 and (treat? or provent? or prophylac?) and (affective or alcohol or
anxiety or (attention deficit) or bipolar or manic or bulimia or (chronic fatigue)
or depression or narcolepsy)

L53 226 FILE USPATFULL

L54 236 FILE CAPLUS

TOTAL FOR ALL FILES

L55 462 L49 AND (TREAT? OR PROVENT? OR PROPHYLAC?) AND (AFFECTIVE OR
ALCOHOL OR ANXIETY OR (ATTENTION DEFICIT) OR BIPOLAR OR MANIC
OR BULIMIA OR (CHRONIC FATIGUE) OR DEPRESSION OR NARCOLEPSY)

=> s 155 and (racemic or (optic? (1w) pure) or metabolite)

L56 100 FILE USPATFULL

L57 19 FILE CAPLUS

TOTAL FOR ALL FILES

L58 119 L55 AND (RACEMIC OR (OPTIC? (1W) PURE) OR METABOLITE)

=> d 157 10-19 hit, hitstr, ibib

L57 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

TI Use of **optically pure** (R)-tofisopam for
treating and preventing **anxiety** disorders, and
composition thereof

AB Methods are disclosed using the R enantiomer of tofisopam. This compound is
useful in the **treatment** or prevention of **anxiety** or
anxiety disorders while substantially reducing adverse effects
associated with **racemic** tofisopam.

ST tofisopam enantiomer **anxiety**

IT Antidepressants

Antipsychotics

Anxiolytics

Drug delivery systems

Enantiomers

((R)-tofisopam for **treating** and preventing **anxiety**
disorders, use with other agents, and compns.)

IT Stress, animal

(acute stress disorder; (R)-tofisopam for **treating** and
preventing **anxiety** disorders, use with other agents, and
compns.)

IT Mental disorder

(agoraphobia; (R)-tofisopam for **treating** and preventing
anxiety disorders, use with other agents, and compns.)

IT Disease, animal

(**anxiety** disorder from general medical condition;
(R)-tofisopam for **treating** and preventing **anxiety**
disorders, use with other agents, and compns.)

IT Drug delivery systems

(capsules; (R)-tofisopam for **treating** and preventing
anxiety disorders, use with other agents, and compns.)

IT Resolution (separation)

(chromatog.; (R)-tofisopam for **treating** and preventing
anxiety disorders, use with other agents, and compns.)

IT Drug delivery systems

(controlled-release; (R)-tofisopam for **treating** and
preventing **anxiety** disorders, use with other agents, and
compns.)

IT Drug delivery systems

(infusions, i.v.; (R)-tofisopam for **treating** and preventing
anxiety disorders, use with other agents, and compns.)

IT Drug delivery systems
(liqs.; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)

IT Mental disorder
(obsession-compulsion; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)

IT Drug delivery systems
(oral; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)

IT **Anxiety**
(panic disorder; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)

IT Mental disorder
(phobia; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)

IT Mental disorder
(post-traumatic stress disorder; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)

IT Therapy
(psychotherapy; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)

IT Behavior
(social, social phobia; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)

IT Drugs
(substance-induced **anxiety** disorder; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)

IT Drug delivery systems
(suspensions; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)

IT Drug delivery systems
(sustained-release; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)

IT Drug delivery systems
(tablets; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)

IT Drug delivery systems
(transdermal; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)

IT Antidepressants
(tricyclic; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)

IT 22345-47-7P, Tofisopam
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation)
((R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)

IT 82059-50-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); FMU (Formation, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); USES (Uses)
((R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)

IT 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine
51-71-8, Phenelzine 72-69-5, Nortriptyline 155-09-9, Tranylcypromine
303-49-1, Clomipramine 438-60-8, Protriptyline 439-14-5, Diazepam
846-49-1, Lorazepam 1668-19-5, Doxepin 3564-66-7, (+)-Trimipramine
10262-69-8, Maprotiline 14028-44-5, Amoxapine 14611-51-9,

(-)-Selegiline 19794-93-5, Trazodone 28981-97-7, Alprazolam
34911-55-2, Bupropion 41935-47-1D, 1,4-Benzodiazepine, derivs.
 54739-18-3, Fluvoxamine 54910-89-3, Fluoxetine 61869-08-7, Paroxetine
 71320-77-9, Moclobemide 79617-96-2, Sertraline 83366-66-9, Nefazodone
 93413-69-5, Venlafaxine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

((R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)

IT 82059-51-6P

RL: PUR (Purification or recovery); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

((R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)


IT **34911-55-2**, Bupropion

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

((R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)

RN 34911-55-2 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 2001:614880 CAPLUS

DOCUMENT NUMBER: 135:147455

TITLE: Use of **optically pure**
 (R)-tofisopam for **treating** and preventing **anxiety** disorders, and composition thereof

INVENTOR(S): Landry, Donald W.; Klein, Donald F.

PATENT ASSIGNEE(S): Janus Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000024400	A1	20000504	WO 1999-US25040	19991027
W:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
RW:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
CA 2348281	AA	20000504	CA 1999-2348281	19991027
BR 9914899	A	20010717	BR 1999-14899	19991027
EP 1124556	A1	20010822	EP 1999-970920	19991027

EP 1124556	B1	20040623		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
GB 2367748	A1	20020417	GB 2001-11739	19991027
JP 2003522112	T2	20030722	JP 2000-578009	19991027
NZ 511744	A	20040430	NZ 1999-511744	19991027
AT 269705	E	20040715	AT 1999-970920	19991027
PT 1124556	T	20041029	PT 1999-970920	19991027
ES 2224751	T3	20050301	ES 1999-970920	19991027
ZA 2001003376	A	20030909	ZA 2001-3376	20010425
HK 1040908	A1	20050422	HK 2002-100988	20020207
PRIORITY APPLN. INFO.:			US 1998-105803P	P 19981027
			WO 1999-US25040	W 19991027
REFERENCE COUNT: 9			THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT	

L57 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

AB A population pharmacokinetic and pharmacodynamic anal. evaluated the relationships of dose, plasma concns. of bupropion and **metabolites**, and patient covariates with the safety and efficacy of bupropion sustained release (SR) for smoking cessation. A total of 519 outpatient chronic cigarette smokers were randomized to one of three bupropion SR doses: 100, 150, or 300 mg/day or placebo. The bupropion plasma concentration time data were fit and subject-specific Bayesian ests. of clearance were obtained. Logistic regression analyses evaluated the role of dose, concns., and covariates in predicting efficacy and safety endpoints. For the evaluation of efficacy, patients were classified as quitters or non-quitters on the basis of a 4-wk quit variable (defined as complete abstinence for weeks 4-7 of the study). For the evaluation of safety, patients were classified into two categories for each adverse event evaluated, corresponding to whether the patient ever experienced the adverse event during the course of the study or never experienced the event, regardless of whether the event was **treatment-emergent**. The efficacy of bupropion SR in facilitating smoking cessation was found to be related to dose and a mean **metabolite** concentration, and quitting in general was found to be related to the number of cigarettes smoked per day at baseline. Smoking cessation was 1.42, 1.69, and 2.84 times more likely in patients receiving 100, 150, and 300 mg/day of bupropion SR, resp., as compared to placebo (p = 0.0001). As the baseline number of cigarettes smoked per day increased, the likelihood of quitting decreased regardless of the **treatment** condition. Insomnia and dry mouth were pos. associated with mean **metabolite** concns., and dry mouth was inversely related to patient weight **Anxiety** was inversely related to predicted steady-state concentration (C_{ps}), suggesting a pos. effect on

this withdrawal symptom. Bupropion SR exhibits a statistically significant dose/plasma level-response relationship for smoking cessation. Dry mouth and insomnia, related to concns., may be managed with dose reduction, with the realization that smoking cessation may be impaired.

IT Antidepressants

Tobacco smoke

(plasma concentration of bupropion sustained release and **metabolites** for smoking cessation in humans)

IT Drug delivery systems

(sustained-release; plasma concentration of bupropion sustained release and **metabolites** for smoking cessation in humans)

IT 31677-93-7, Zyban

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(plasma concentration of bupropion sustained release and **metabolites** for smoking cessation in humans)

IT 54-11-5, Nicotine


RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(plasma concentration of bupropion sustained release and **metabolites** for smoking cessation in humans)

IT 92264-82-9 99102-04-2
RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(plasma concentration of bupropion sustained release and **metabolites** for smoking cessation in humans)

IT 31677-93-7, Zyban
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(plasma concentration of bupropion sustained release and **metabolites** for smoking cessation in humans)

RN 31677-93-7 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

ACCESSION NUMBER: 2001:605974 CAPLUS
DOCUMENT NUMBER: 135:340398
TITLE: Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation
AUTHOR(S): Johnston, J. Andrew; Fiedler-Kelly, Jill; Glover, Elbert D.; Sachs, David P. L.; Grasela, Thaddeus H.; De Veauugh-Geiss, Joseph
CORPORATE SOURCE: Glaxo Wellcome Inc., Research Triangle Park, NC, 27709, USA
SOURCE: Nicotine & Tobacco Research (2001), 3(2), 131-140
CODEN: NTREF6; ISSN: 1462-2203
PUBLISHER: Carfax Publishing
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L57 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

TI Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion **treatment**

AB Bupropion is widely used in the **treatment** of **depression** and as an anti-craving medication for the cessation of tobacco smoking. Because it is a very weak inhibitor of norepinephrine (NE) and dopamine (DA) reuptake, its mechanisms of action remain to be elucidated. Bupropion was administered s.c. via osmotic minipumps over 2 days to determine its effects on the spontaneous firing activity of NE, serotonin (5-HT), and DA neurons in the brain of anesthetized male Sprague-Dawley rats. This **treatment** was used to obtain levels of the parent compound

and its putatively active **metabolites** that would more adequately reflect the clin. condition than utilizing acute injections. When given by minipump for 2 days, bupropion produced a dose-dependent attenuation of the mean spontaneous firing NE neurons (7.5 mg/kg per day: 15%; 15 mg/kg per day: 61%; 30 mg/kg per day: 80%) which was reversed by the α 2-adrenoceptor antagonist idazoxan. At the highest regimen, the mean firing rate of 5-HT neurons was 100% higher than in control rats, but unaffected in NE-lesioned rats. In contrast, DA neurons in the ventral tegmental area displayed a normal firing rate during the latter bupropion **treatment**. Sustained bupropion administration decreased the firing rate of NE neurons due to an increased activation of their inhibitory somatodendritic α 2-adrenoceptors. This effect of the bupropion **treatment** would be attributable mainly to an enhancement of NE release and not to reuptake inhibition. This contention is based essentially on the observation that NE reuptake blockers leave unaltered the firing rate of 5-HT neurons, whereas bupropion enhanced it via a NE-dependent mechanism. The present study did not put into evidence any DA activity of bupropion at the level of the cell body of mesolimbic/cortical DA neurons at a regimen exerting profound alterations of the firing activity of NE and 5-HT neurons.

- IT Nerve
(dopaminergic; modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion **treatment**)
- IT Nerve
(neuron, norepinephrine; modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion **treatment**)
- IT Nerve
(serotonergic; modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion **treatment**)
- IT Adrenoceptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α 2; modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion **treatment**)
- IT 34911-55-2, Bupropion
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion **treatment**)
- IT 50-67-9, Serotonin, biological studies 51-41-2, Norepinephrine
51-61-6, Dopamine, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion **treatment**)
- IT 34911-55-2, Bupropion
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion **treatment**)
- RN 34911-55-2 CAPLUS
- CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)



DOCUMENT NUMBER: 135:147350
 TITLE: Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion **treatment**
 AUTHOR(S): Dong, Jianming; Blier, Pierre
 CORPORATE SOURCE: Department of Psychiatry and Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL, 32610, USA
 SOURCE: Psychopharmacology (Berlin, Germany) (2001), 155(1), 52-57
 CODEN: PSCHDL; ISSN: 0033-3158
 PUBLISHER: Springer-Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
 TI Methods and compositions for **treating** or preventing sleep disturbances using very low doses of cyclobenzaprine
 AB Methods and compns. comprising a very low dose of cyclobenzaprine or **metabolite** thereof are provided for preventing and **treating** sleep disturbances and illnesses manifested with sleep dysfunction, including fibromyalgia syndrome, **chronic fatigue** syndrome, sleep disorders, psychogenic pain disorders or chronic pain syndromes or symptoms thereof. Also provided are methods and compns. for **treating** sleep disturbances, chronic pain or fatigue in humans suffering from fibromyalgia syndrome, **chronic fatigue** syndrome, sleep disorders, psychogenic pain disorders, chronic pain syndromes using a very low dose of cyclobenzaprine.
 IT Antidepressants
 (atypical; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)
 IT Drug delivery systems
 (capsules; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)
 IT Fatigue, biological
 (**chronic fatigue** syndrome; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)
 IT Pain
 (chronic; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)
 IT Phototherapy
 (combination with light-box therapy; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)
 IT Therapy
 (combination with psychotherapy; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)
 IT Analgesics
 Anti-inflammatory agents
 Anxiety
 Autoimmune disease
 Fatigue, biological
 Stress, animal
 (cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)
 IT Sleep
 (disorder; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)
 IT Muscle, disease
 (fibromyalgia; cyclobenzaprine in low dose for **treating** or

preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT Drug delivery systems
(oral; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT Drug delivery systems
(parenterals; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT Drug delivery systems
(prodrugs; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT Pain
(psychogenic; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT Drugs
(sleep disturbance associated with; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT Drug delivery systems
(tablets; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT Antidepressants
(tricyclic; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT Drug delivery systems
(unit doses; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 72-69-5, Nortriptyline 303-49-1, Clomipramine 303-53-7, Cyclobenzaprine 303-53-7D, Cyclobenzaprine, **metabolites** and prodrugs 438-60-8, Protriptyline 739-71-9, Trimipramine 1668-19-5, Doxepin 6202-23-9, Cyclobenzaprine hydrochloride 10262-69-8, Maprotiline 14028-44-5, Amoxapine 19794-93-5, Trazodone 34911-55-2, Bupropion 54739-18-3, Fluvoxamine 54910-89-3, Fluoxetine 59729-33-8, Citalopram 61718-82-9, Fluvoxamine maleate 61869-08-7, Paroxetine 71620-89-8, Reboxetine 79617-96-2, Sertraline 83366-66-9, Nefazodone 93413-69-5, Venlafaxine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT 50-67-9, Serotonin, biological studies 51-41-2, Norepinephrine 51-61-6, Dopamine, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(reuptake inhibitors; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT 50-06-6, Phenobarbital, biological studies 57-43-2, Amobarbital 58-25-3, Chlordiazepoxide 64-17-5, Ethanol, biological studies 67-52-7D, Barbituric acid, derivs. 76-73-3, Secobarbital 76-74-4, Pentobarbital 77-02-1, Aprobital 115-38-8, Mephobarbital 115-44-6, Talbutal 125-40-6, Butabarbital 439-14-5, Diazepam 604-75-1, Oxazepam 846-49-1, Lorazepam 846-50-4, Temazepam 1622-61-3, Clonazepam 1622-62-4, Flunitrazepam 2955-38-6, Prazepam 12794-10-4D, Benzodiazepine, derivs. 17617-23-1, Flurazepam 23092-17-3, Halazepam 23887-31-2, Clorazepate 28911-01-5, Triazolam 28981-97-7, Alprazolam 36735-22-5, Quazepam 59467-70-8, Midazolam

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sleep disturbance associated with; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT 34911-55-2, Bupropion


RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

RN 34911-55-2 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 2001:137009 CAPLUS

DOCUMENT NUMBER: 134:173051

TITLE: Methods and compositions for **treating** or preventing sleep disturbances using very low doses of cyclobenzaprine

INVENTOR(S): Iglehart, Iredell W., III

PATENT ASSIGNEE(S): Vela Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012175	A1	20010222	WO 2000-US22082	20000811
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2380432	AA	20010222	CA 2000-2380432	20000811
BR 2000013017	A	20020416	BR 2000-13017	20000811
EP 1202722	A1	20020508	EP 2000-953996	20000811
EP 1202722	B1	20050713		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
GB 2368522	A1	20020508	GB 2002-2908	20000811
US 6395788	B1	20020528	US 2000-637557	20000811
JP 2003506484	T2	20030218	JP 2001-516521	20000811
ES 2192156	A1	20030916	ES 2002-50016	20000811
ES 2192156	B1	20050216		
NZ 516749	A	20040326	NZ 2000-516749	20000811
AT 299369	E	20050715	AT 2000-953996	20000811
US 2001046988	A1	20011129	US 2001-893758	20010627
US 6541523	B2	20030401		
ZA 2002000619	A	20030423	ZA 2002-619	20020123
ZA 2002000852	A	20030430	ZA 2002-852	20020130
US 2004029869	A1	20040212	US 2003-392366	20030317
PRIORITY APPLN. INFO.:			US 1999-148881P	P 19990813
			US 2000-637557	A3 20000811

WO 2000-US22082 W 20000811

US 2001-893758 A3 20010627

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

AB Several studies in mid-life adults have suggested a curvilinear relationship between bupropion plasma concentration and antidepressant response.

Similarly, elevated levels of bupropion's major **metabolites** have been associated with reduced antidepressant response and increased side effects. These studies have been limited by use of ascending dose designs. We conducted a prospective, randomized, double-blind, fixed-dose study of bupropion **treatment** in 15 elderly subjects diagnosed with major **depression**. Concentration of bupropion and hydroxybupropion (HB), erythropropion (EB), and threobupropion (TB) were determined by high performance liquid chromatog. We found bupropion plasma concns. less than 30 ng/mL predicted antidepressant response. Poor antidepressant response was associated with elevated levels of EB and TB, but not HB. Total **metabolite** concentration (HB+EB+TB) was also correlated with severity of adverse side effects. Therapeutic drug monitoring may offer advantages when **treating** older individuals with bupropion, with optimal antidepressant response at bupropion plasma concns. less than 30 ng/mL.

IT Mental disorder

(**depression**, major; bupropion plasma concentration and antidepressant response in elderly patients)

IT 31677-93-7, Wellbutrin

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(bupropion plasma concentration and antidepressant response in elderly patients)

IT 92264-81-8 92264-82-9 99102-04-2

RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)


(**metabolite** of bupropion; bupropion plasma concentration and antidepressant response in elderly patients)

IT 31677-93-7, Wellbutrin

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(bupropion plasma concentration and antidepressant response in elderly patients)

RN 31677-93-7 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

ACCESSION NUMBER: 2001:120957 CAPLUS
DOCUMENT NUMBER: 135:175084

TITLE: Bupropion plasma concentration and antidepressant response in elderly patients: A prospective, randomized, double-blind study

AUTHOR(S): Adeoye, O. M.; Sweet, R. A.; Pollock, B. G.; Miller, M. D.; Mulsant, B. H.; Kastango, K. B.; Reynolds, C. F.

CORPORATE SOURCE: Geriatric Psychopharmacology Program, Intervention Research Center for Late-Life Mood Disorders, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

SOURCE: International Journal of Geriatric Psychopharmacology (2000), 2(3), 132-136
CODEN: IJGPFT; ISSN: 1364-8233

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

TI Bupropion **metabolites** and methods of their synthesis and therapeutic uses and compositions

AB Methods and compns. are disclosed which utilize **metabolites** of bupropion for **treating** disorders ameliorated by inhibition of neuronal monoamine reuptake. Such disorders include, but are not limited to, erectile dysfunction, **affective** disorders, cerebral function disorders, cigarette smoking, and incontinence. The invention further discloses methods of making **optically pure** bupropion **metabolites**.

ST bupropion **metabolite** synthesis **treatment** monoamine reuptake disorder; erectile dysfunction **treatment** bupropion **metabolite**; **affective** disorder **treatment** bupropion **metabolite**; cigarette smoking **treatment** bupropion **metabolite**; incontinence **treatment** bupropion **metabolite**; **optically pure** bupropion **metabolite**

IT 5-HT antagonists
(5-HT3, adjunctive administration with; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Antiemetics
(adjunctive administration with; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Mental disorder
(**affective**, **treatment** of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Anticonvulsants
Antidepressants
Antiparkinsonian agents
(bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Drug delivery systems
(capsules; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Brain, disease
(cerebrum, **treatment** of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Mental disorder
(**depression**, **treatment** of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Sexual behavior
(impotence, **treatment** of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Bladder
(incontinence, **treatment** of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Drug delivery systems
(mucosal; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Sleep
(**narcolepsy**, **treatment** of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Drug delivery systems
(oral; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Behavior
(smoking, cessation of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Drug delivery systems
(solids; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Drug delivery systems
(solns.; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Drug delivery systems
(tablets; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Drug delivery systems
(transdermal patches; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Drug delivery systems
(transdermal; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Nerve
(**treating** disorder ameliorated by inhibition of monoamine reuptake in; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Monoamines
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(**treating** disorder ameliorated by inhibition of neuronal reuptake of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Epilepsy
Parkinson's disease
(**treatment** of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Biological transport
(uptake, **treating** disorder ameliorated by inhibition of neuronal monoamine reuptake; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 364-62-5, Metoclopramide 89565-68-4, Tropisetron 90182-92-6, Zacopride 99614-02-5, Ondansetron 109889-09-0, Granisetron 112727-80-7, Renzapride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adjunctive administration with; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 34911-55-2, Bupropion 119802-68-5 292055-72-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 153365-82-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 102141-12-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 358-23-6, Trifluoromethane sulfonic anhydride
 RL: NUU (Other use, unclassified); USES (Uses)
 (bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 124-68-5, 2-Amino-2-methyl-1-propanol 34841-35-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 291275-45-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 287477-53-6P 291275-46-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 192374-15-5P 292055-71-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 34911-55-2DP, Bupropion, **metabolites**
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 291275-47-3 291275-48-4 291275-49-5 291275-50-8 291275-51-9
 291275-52-0
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 51-41-2, Norepinephrine
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (inhibition of reuptake of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 50-67-9, Serotonin, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (second pharmacol. active compds. of inhibitors of reuptake of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 51-61-6, Dopamine, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (treating disorder ameliorated by inhibition of neuronal reuptake of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)


IT 54-11-5, Nicotine
 RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (treatment of addiction to; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 34911-55-2, Bupropion 292055-72-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(bupropion **metabolites** and methods of synthesis and therapeutic uses and comps.)

RN 34911-55-2 CAPLUS


CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)



RN 292055-72-2 CAPLUS

CN Benzenemethanol, 3-chloro- α -[(1S)-1-[(1,1-dimethylethyl)amino]ethyl]-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 153365-82-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(bupropion **metabolites** and methods of synthesis and therapeutic uses and comps.)

RN 153365-82-3 CAPLUS

CN Benzenemethanol, 3-chloro- α -[(1R)-1-[(1,1-dimethylethyl)amino]ethyl]-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 102141-12-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bupropion **metabolites** and methods of synthesis and therapeutic uses and comps.)

RN 102141-12-8 CAPLUS

CN Benzenemethanol, 3-chloro- α -[(1S)-1-[(1,1-dimethylethyl)amino]ethyl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 292055-71-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(bupropion **metabolites** and methods of synthesis and
therapeutic uses and compns.)

RN 292055-71-1 CAPLUS

CN Benzenemethanol, 3-chloro- α -[(1S)-1-[(1,1-dimethylethyl)amino]ethyl]-
, hydrochloride, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

IT 34911-55-2DP, Bupropion, **metabolites**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
study); PREP (Preparation); USES (Uses)
(bupropion **metabolites** and methods of synthesis and
therapeutic uses and compns.)

RN 34911-55-2 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA
INDEX NAME)



ACCESSION NUMBER: 2000:627938. CAPLUS

DOCUMENT NUMBER: 133:227784

TITLE: Bupropion **metabolites** and methods of their
synthesis and therapeutic uses and compositions

INVENTOR(S): Jerussi, Thomas P.; McCullough, John R.; Senanayake,
Chrisantha H.; Fang, Qun K.

PATENT ASSIGNEE(S): Sepracor Inc., USA


SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

L34 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 357399-43-0 REGISTRY
ED Entered STN: 19 Sep 2001
CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-Hydroxy-2-(3-chlorophenyl)-3,5,5-trimethylmorpholine.
FS 3D CONCORD
MF C13 H18 Cl N O2
SR CA
LC STN Files: CA, CAPLUS, CHEMCATS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)